Cholinesterases; ACHE & BCHE · SELECTIVITY GROUP · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Cholinesterases; ACHE & BCHE shows approved-linked disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P06276. Start with Alzheimer disease, then reuse UniProt P06276 as the stable protein anchor across project notes and exports.
Start with Alzheimer disease, then reuse UniProt P06276 as the stable protein anchor across project notes and exports.
Cholinesterases; ACHE & BCHE shows approved-linked disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with Alzheimer disease because it currently carries approved-linked support. Linked drugs include RIVASTIGMINE, RIVASTIGMINE TARTRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCholinesterase
Review this target as Cholinesterases; ACHE & BCHE, mapped to UniProt P06276. ChEMBL maps the protein component as Cholinesterase. Sequence length is 602 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cholinesterases; ACHE & BCHE as ChEMBL target CHEMBL2095233, mapped to UniProt P06276. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Cholinesterases; ACHE & BCHE is the right protein anchor across sources, using UniProt P06276 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Alzheimer disease is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Cholinesterases; ACHE & BCHE |
| Target Type | SELECTIVITY GROUP |
| Organism | Homo sapiens |
| UniProt | P06276 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Cholinesterase |
| UniProt Accession | P06276 |
| Component Type | Protein |
| Sequence Length | 602 aa |
Cholinesterase
Review this target as Cholinesterases; ACHE & BCHE, mapped to UniProt P06276. ChEMBL maps the protein component as Cholinesterase. Sequence length is 602 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Cholinesterases; ACHE & BCHE shows approved-linked disease relevance led by Alzheimer disease. 5 more disease programs remain visible in the same review block.
Start review with Alzheimer disease because it currently carries approved-linked support. Linked drugs include RIVASTIGMINE, RIVASTIGMINE TARTRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 54 | 0 | — |
| protein format | 54 | 0 | — |
| cell-based format | 2 | 0 | — |